quinuclidines has been researched along with Triple Negative Breast Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, S; Chang, JT; Davies, PJ; Echeverria, G; Feng, N; Giuliani, V; Guo, L; Heffernan, TP; Jiang, Y; Liu, X; Ma, X; Marszalek, JR; Moulder, S; Piwnica-Worms, H; Powell, RT; Qi, Y; Redwood, A; Stephan, C; Symmans, WF; Tu, Y; Vellano, CP; White, JB; Zhang, X; Zhou, X | 1 |
| Kalimutho, M; Khanna, KK; Makhale, A; Nanayakkara, D; Raninga, P | 1 |
| Amati, B; Amato, A; Ciani, Y; Dalla, E; Del Sal, G; Eterno, V; Gaweda-Walerych, K; Ingallina, E; Lisek, K; Morelli, MJ; Piazza, S; Rajkowska, K; Rosato, A; Sommaggio, R; Tonelli, C; Walerych, D; Wiśniewski, JR; Zambelli, A | 1 |
| Crown, J; Duffy, MJ; Gallagher, WM; Kiely, M; Kiely, PA; McGowan, PM; Murray, A; O'Connor, DP; O'Donovan, N; Synnott, NC | 1 |
4 other study(ies) available for quinuclidines and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Repositioning; Female; Heterografts; High-Throughput Screening Assays; Humans; Kinesins; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Transplantation; Quinuclidines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer.
Topics: Apoptosis; Benzothiazoles; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA Replication; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Naphthyridines; Quinuclidines; RNA Polymerase I; Triple Negative Breast Neoplasms | 2021 |
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
Topics: Animals; Antineoplastic Agents; Humans; Mice; MicroRNAs; Mutant Proteins; Mutation, Missense; Neoplasm Metastasis; NF-E2-Related Factor 2; Oligopeptides; Proteasome Endopeptidase Complex; Proteome; Quinuclidines; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2016 |
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Topics: Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Mutation; Quinuclidines; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2017 |